MaxCyte, Inc. (MXCT)

3,7100 +0,0500 (+1,37%) A partir del 10:37AM EDT. Mercado abierto.

MaxCyte, Inc.

9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700
https://www.maxcyte.com

Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 143

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Douglas Arthur Doerfler	Founder	2,34M	N/A	1956
Mr. Douglas J. Swirsky CFA, CPA	Chief Financial Officer	607,42k	N/A	1969
Mr. Jay Gelfman	Senior Vice President of Operations	N/A	N/A	N/A
Mr. Ronald Evan Holtz CPA, Ph.D.	Executive Vice President of Administration	649,38k	N/A	1958

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Gobierno corporativo

El ISS Governance QualityScore de MaxCyte, Inc., a día 29 de abril de 2024, es 6. Las puntuaciones base son Auditoría: 1; Tablero: 8; Derechos de los accionistas: 8; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.